Výsledky vyhledávání - Francesca Avogadri-Connors

  • Zobrazuji výsledky 1 - 4 z 4
Upřesnit hledání
  1. 1
    HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i>

    HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> Autor Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Paul Dent

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

    Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype Autor Daniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano, Cailian Liu, Feng Zhao, Hong Zhong, Alexander M. Lesokhin, Francesca Avogadri-Connors, Jianda Yuan, Yanyun Li, Alan N. Houghton, Taha Merghoub, Jedd D. Wolchok

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

    Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial Autor Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González-Ericsson, Melinda E. Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

    Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) Autor Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Helen Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie Shifman, Ivana Sarotto, Peter Savas, Michael J. Wick, Kyriakos P. Papadopoulos, Alyssa Moriarty, Richard E. Cutler, Francesca Avogadri-Connors, Alshad S. Lalani, Richard Bryce, Sarat Chandarlapaty, David M. Hyman, David B. Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F. Berger, Filippo Montemurro, Maurizio Scaltriti

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: